ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
Obstructive sleep apnea (OSA), a global public health issue marked by repeated upper airway collapse during sleep, is tied to diverse diseases-from cardiovascular conditions to cancer.
Detailed price information for Inspire Medical Systems Inc (INSP-N) from The Globe and Mail including charting and trades.
Inspire Medical Systems, which produces an implant to treat sleep apnea, extended the run spots involving the Golden Bachelorette winner through the holidays.
Undiagnosed sleep apnea in women has reached a tipping point, with emerging sex-specific sleep research poised to reshape how ...
Medical and behavioral health specialists in Florida can review your sleep patterns to help you sleep better. Some of those experts will be available at the Sun Sentinel’s PRIME Expo on ...
TipRanks on MSN
Inspire Medical’s New Study on Sleep Apnea in Down Syndrome Patients: A Market Game Changer?
Inspire Medical (($INSP)) announced an update on their ongoing clinical study. Inspire Medical Systems, Inc. has launched the Pediatric Down ...
The drug sulthiame reduces the number of breathing pauses and improves sleep quality in patients with obstructive sleep apnea, according to a European clinical study in which the University of ...
For the first time, researchers have shown that tackling obstructive sleep apnea’s two root causes at once, using both oxygen and a jaw-forwarding device, can dramatically cut breathing interruptions ...
Combined treatments for both aspects of obstructive sleep apnea (OSA)—a compromised airway anatomy and unstable breathing—have shown promise in a Monash and Harvard-led trial. Published in the ...
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 2 minutes ...
Plaintiffs are going to court to challenge CVS Caremark’s decision to stop covering Zepbound, a weight-loss drug that is also used to treat sleep apnea. Plaintiff Martin Hamburger filed his lawsuit in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results